RxDoctor Payments Data

Kristin Pego, NP

Adult Health · New York, NYNPI 1508178179

Payments from drug & device makers

$3,066in general payments, 2019–2025

Across 70 payments — averaging $43.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pharmaessentia USA Corporation$1K
  • Sanofi$648
  • Johnson & Johnson$344
  • AstraZeneca$208
  • Mirati Therapeutics, Inc.$168
  • Incyte Corporation$82
  • plus $410 from 11 others

What the payments were for

  • Consulting fees$58319%
  • Speaking & faculty fees$92330%
  • Food & beverage$1,43547%
  • Education$1264%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,066 in reported general payments places this provider in the 85th percentile of 3,828 adult health providers in New York.

See all adult health providers in New York

Medicare billing

Part B allowed, 2024
$4,046
Medicare patients
30
Services billed
80

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JakafiRuxolitinib Phosphate14$467,732
Lenalidomide29$434,019
NinlaroIxazomib Citrate30$389,618
ImbruvicaIbrutinib19$350,180
CalquenceAcalabrutinib Maleate20$297,063
RevlimidLenalidomide11$190,026
XareltoRivaroxaban61$57,385
EliquisApixaban53$44,446
ProcritEpoetin Alfa12$44,223
Acyclovir54$891
Hydroxyurea31$860
Anastrozole25$307
Dexamethasone11$223
Famotidine12$205
Alprazolam15$91

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Incyte CorporationJakafi$82$467,73214 claims
AstraZenecaCalquence$208$297,06320 claims
Bristol Myers SquibbRevlimid$77$190,02611 claims
Johnson & JohnsonXarelto, Procrit$344$101,60873 claims
PfizerEliquis$40$44,44653 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,828 adult health providers in New York.

Other adult health in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →